Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ImmunoPrecise Antibodies Ltd.

< Previous 1 2 3 Next >
IPA Announces Closing of $1.265 Million Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Announces Proposed Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Provides Update on Growth Strategy and Recent Share Price Movement
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Announces CFO Transition
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Announces Board Refreshment
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Responds to 13D Filing
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023
From IMMUNOPRECISE ANTIBODIES LTD.
Via Business Wire
Tickers IPA
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA TSX-V:IPA
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.